Chemotherapy in the Management of Advanced Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients: Theoretical and Practical Considerations

Abstract

The head and neck surgery and oncology literature is rich with experience in locoregionally advanced and metastatic HNSCC, and adaptation of management concepts may prove feasible in the management of OTRs with advanced and metastatic cutaneous SCC.

The promise of molecular targeted therapies: Protein kinase inhibitors in the treatment of cutaneous malignancies

“…Patients with SCC in general who have nodal or metastatic disease have a 5-year survival of 14% to 39% compared with 25% to 40% in SCCHN. 20 Martinez et al 20 argue that because both cutaneous SCC and SCCHN have lymphatic spread and progress rapidly despite therapy, SCC with nodal disease is no different from SCCHN with nodal involvement. Therefore, these authors contend that therapies of SCCHN may be applicable to metastatic SCC.…”

Management of Widely Metastatic and Unresectable Cutaneous Squamous Cell Carcinoma

“…It is usually combined with radiation and is most often used for organ preservation or for patients unable to tolerate surgery. The most common defi nitive chemotherapy regimens include cisplatin, 5-FU/cisplatin combinations, 5-FU/carboplatin combinations, and paclitaxel/carboplatin combinations [ 28 ]. Most studies evaluating these regimens have been performed in mucosal head and neck SCCs (originating from the oral cavity, oropharynx, hypopharynx, and larynx).…”

“…Induction chemotherapy is generally used in conjunction with radiation. The most frequently used induction chemotherapy regimens are 5-fl uorouracil (5-FU)/cisplatin combinations [ 28 ].…”

Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in Survivin Expression

“…First-line therapy for locally advanced HNSCC is typically surgery and/or radiotherapy (3,4). However, radical surgery for HNSCC is difficult and disfiguring (3). In addition, tumors recur after first-line therapy in approximately one third of all patients with HNSCC, underscoring the need for more effective treatment strategies.…”

“…In the United States, the annual incidence is estimated to be 31,000 with f7,400 associated deaths (2). First-line therapy for locally advanced HNSCC is typically surgery and/or radiotherapy (3,4). However, radical surgery for HNSCC is difficult and disfiguring (3).…”